Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Curr Opin Virol. 2023 Oct;62:101347. doi: 10.1016/j.coviro.2023.101347. Epub 2023 Aug 19.
The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.
早期 COVID-19 疫苗在减轻疾病严重程度方面的有效性促使人们专注于开发新一代疫苗，以预防病毒感染和传播。一种有前途的方法是通过鼻腔给药诱导黏膜免疫，目前正在开发使用不同平台的多种黏膜疫苗候选物。活减毒病毒是 SARS-CoV-2 的致病性较弱的版本，作为一种黏膜疫苗平台具有很大的潜力，可以诱导已经接种过 mRNA 疫苗的个体产生混合免疫。这篇综述讨论了使用活减毒 SARS-CoV-2 鼻内疫苗的潜在益处和注意事项，并强调了作者在开发这种疫苗平台方面的工作。
